|Podcasts|January 19, 2011
Build A Drug's Value in Early
Advertisement
Build a Drug's Value in Early
Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
2
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
3
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
4
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
5